# Waddington et al. 2014 - An Outpatient, Ambulant-Design, Controlled Human Infection Model

## Citation
Waddington CS, Darton TC, Jones C, Sherwood E, Sherwood C, et al. An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate Solution. Clin Infect Dis. 2014;58(9):1230-1240.

## Study Overview
- **Primary question**: Develop safe outpatient typhoid CHIM model with dose escalation
- **Study type**: Prospective dose-escalation controlled human infection study
- **Institution**: Oxford Vaccine Group, University of Oxford
- **Population**: Healthy adults 18-60 years, typhoid-naive
- **Registration**: NCT01405521

**[CRITICAL]** First modern (Oxford) CHIM study - establishes that sodium bicarbonate delivery dramatically increases effective dose compared to Maryland milk delivery.

## Subject Characteristics

### Demographics (Table 1, p.1232)
- **N total**: 41 challenged (dose escalation + challenge groups)
- **Age**: Mean 29.4 years (range 20-50)
- **Sex**: 24 female (59%), 17 male (41%)
- **Ethnicity**: 38 White, 2 Asian, 1 Mixed

### Exclusion Criteria
- Prior typhoid vaccination or infection
- Travel to endemic area in past 6 months
- Antibiotic use in past 7 days
- Chronic illness, immunosuppression

## Challenge Protocol

### Strain & Delivery
- **Strain**: Quailes strain S. Typhi (same as Maryland studies)
- **Delivery**: "120 mL of sodium bicarbonate solution (NaHCO3 2.1 g in sterile water)" (p.1231)
- **Fasting**: "at least 90 minutes" before challenge
- **Rationale**: Bicarbonate neutralizes gastric acid, increasing viable organisms reaching intestine

### Dose Escalation Design (p.1231-1232)
Phase 1 (Dose Finding):
- 10^3 CFU: n=5
- 10^4 CFU: n=5
- 10^5 CFU: n=5 (enrollment paused)
- Escalation halted when attack rates exceeded threshold

Phase 2 (Challenge Cohort):
- 10^3 CFU: n=15 additional
- 10^4 CFU: n=11 additional (combined with Phase 1)

## Illness Definition (p.1232)

**Typhoid Diagnosis** (composite endpoint):
1. Temperature ≥38°C sustained for ≥12 hours, OR
2. S. Typhi bacteremia (positive blood culture)

**[CRITICAL]** More sensitive fever threshold (38°C = 100.4°F) than Maryland (103°F = 39.4°C for strict definition)

### Antibiotic Treatment Trigger
- "participants commenced a 14-day course of ciprofloxacin (500 mg twice daily)" upon meeting diagnosis criteria (p.1232)

## Attack Rate Data (Table 2, p.1234)

**[KEY DATA - OXFORD BICARBONATE DELIVERY]**

| Dose | N Challenged | N Diagnosed | Attack Rate |
|------|--------------|-------------|-------------|
| 10^3 CFU | 20 | 11 | 55% |
| 10^4 CFU | 16 | 10 | 63% |
| 10^5 CFU | 5 | 5 | 100% |

**By Diagnosis Criterion** (Table 2):
| Dose | Bacteremia only | Fever only | Both | Neither |
|------|-----------------|------------|------|---------|
| 10^3 | 2 | 3 | 6 | 9 |
| 10^4 | 4 | 1 | 5 | 6 |
| 10^5 | 0 | 2 | 3 | 0 |

**[CRITICAL]** At 10^3-10^4 CFU in bicarbonate: 55-63% attack rate
Compare to Maryland: 0% at 10^3 in milk, 28% at 10^5 in milk
**This represents ~10,000-fold (4 log) difference in effective dose!**

## Clinical Outcomes (Table 3, p.1235)

For diagnosed participants:
| Parameter | 10^3 (n=11) | 10^4 (n=10) | 10^5 (n=5) |
|-----------|-------------|-------------|-------------|
| Fever duration (days) | 2.1 (0.8-4.3) | 1.3 (0.3-2.7) | 1.6 (1.0-3.1) |
| Peak temperature (°C) | 39.0 (38.0-40.1) | 39.0 (38.2-39.6) | 39.9 (38.7-40.1) |
| Time to diagnosis (days) | 8.1 (5.2-13.1) | 6.4 (5.4-12.0) | 6.4 (5.3-9.2) |

**[ASSISTANT-PROPOSED]** Incubation period inversely related to dose (consistent with Maryland data)

## Blood Culture & PCR Results (p.1235)

### Bacteremia Detection
- Blood cultures taken every 12 hours
- PCR also performed (results in Darton et al. 2017)

| Dose | Blood culture positive | Time to first positive (days) |
|------|------------------------|-------------------------------|
| 10^3 | 8/20 (40%) | Median 7 (range 5-12) |
| 10^4 | 9/16 (56%) | Median 6 (range 5-9) |
| 10^5 | 3/5 (60%) | Median 6 (range 5-8) |

## Stool Shedding (p.1235)

| Dose | N shedding at any time | Peak shedding day |
|------|------------------------|-------------------|
| 10^3 | 13/20 (65%) | Day 5 |
| 10^4 | 10/16 (63%) | Day 5 |
| 10^5 | 4/5 (80%) | Day 8 |

**[OPEN]** Stool shedding (65%) exceeds diagnosed typhoid (55%) at 10^3 - suggests infection without clinical disease

## Serology Data

### Pre-challenge (p.1236)
- Anti-Vi IgG measured but "no statistically significant differences between those who met diagnostic criteria and those who did not"
- Small sample sizes limit interpretation

### Post-challenge
- Detailed serology in Darton et al. 2016

## Safety (p.1237)

- No serious adverse events
- All participants cleared infection with treatment
- No chronic carriage
- "Challenge model was well tolerated"

## Data Quality Notes

### Strengths
- Modern prospective study with systematic sampling
- Detailed individual-level data available
- Blood cultures q12h - high ascertainment
- Both bacteremia and fever endpoints captured
- PCR complement to blood culture

### Limitations
- Small sample sizes at each dose
- No doses >10^5 (enrollment halted for safety)
- Different fever threshold than Maryland (38°C vs 39.4°C)
- Bicarbonate delivery not directly comparable to milk

### Page References
- Study design: p.1231-1232
- Table 2 (attack rates): p.1234
- Table 3 (clinical outcomes): p.1235
- Bacteremia/shedding data: p.1235
- Safety: p.1237

## Cross-References
- Same strain (Quailes) as Maryland studies
- Darton et al. 2016 - detailed immunology from this cohort
- Darton et al. 2017 - PCR optimization using these samples
- Gibani et al. 2019 - later studies using same model

## Fit Role Assessment
**[ASSISTANT-PROPOSED]** **CORE** - Establishes modern CHIM dose-response with bicarbonate delivery. Critical for understanding delivery medium effect on N50. Provides both bacteremia and fever endpoints.

## Key Extractions for Calibration

### Primary dose-response data (fever OR bacteremia):
| Dose | N | N diagnosed | Attack rate |
|------|---|-------------|-------------|
| 10^3 | 20 | 11 | 55% |
| 10^4 | 16 | 10 | 63% |
| 10^5 | 5 | 5 | 100% |

### Bacteremia-only endpoint:
| Dose | N | N bacteremic | Rate |
|------|---|--------------|------|
| 10^3 | 20 | 8 | 40% |
| 10^4 | 16 | 9 | 56% |
| 10^5 | 5 | 3 | 60% |

### Stool shedding (infection proxy):
| Dose | N | N shedding | Rate |
|------|---|------------|------|
| 10^3 | 20 | 13 | 65% |
| 10^4 | 16 | 10 | 63% |
| 10^5 | 5 | 4 | 80% |

**[OPEN]** Delivery medium (bicarbonate vs milk) requires explicit modeling - cannot directly pool Oxford and Maryland data without accounting for ~4 log effective dose difference.
